Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | SCN4A | P35499 | 2/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.47 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290683 | 0.84 | SOS1 (0.58) | CYP3A4SCN4ASOS1HSPB1LTA4H | |
| SCHEMBL6289867 | 0.84 | SOS1 (0.58) | CYP3A4SCN4ASOS1HSPB1LTA4H | |
| SCHEMBL351854 | 0.84 | SOS1 (0.58) | CYP3A4SCN4ASOS1HSPB1LTA4H | |
| SCHEMBL8540552 | 0.84 | LMNA (0.47) | CYP3A4LTA4HMEN1KMT2ASCN9A | |
| SCHEMBL7367702 | 0.81 | SOS1 (0.56) | CYP3A4SCN4ASOS1HSPB1LTA4H | |
| SCHEMBL29375733 | 0.81 | SOS1 (0.56) | CYP3A4SCN4ASOS1HSPB1LTA4H | |
| SCHEMBL29170634 | 0.78 | SOS1 (0.54) | CYP3A4SCN4ASOS1HSPB1LTA4H | |
| SCHEMBL12362975 | 0.78 | KMT2A (0.57) | MAPK14CYP3A4S1PR2GAAMEN1 | |
| SCHEMBL14355080 | 0.78 | CYP11B1 (0.54) | MAPK14CYP3A4SCN4ACA12CA1 | |
| SCHEMBL30047550 | 0.77 | LTA4H (0.63) | MAPK14CYP3A4SCN4ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2022-09-22 | — | — | US | disclosed |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-5169855-A | PIPERIDINE ETHER DERIVATIVES AS PSYCHOTROPIC DRUGS OR PLANT FUNGICIDES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| EP-0449187-A2 | Piperidin ether derivatives as psychotropic drugs or plant fungicides | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| US-4411904-A | Diphenylpropanamines, compositions thereof and use thereof | WARNER-LAMBERT COMPANY (US) | 1983-10-25 | — | — | US | disclosed |
| US-4364954-A | NEUROLEPTIC AGENT | WARNER-LAMBERT COMPANY (US) | 1982-12-21 | — | — | US | disclosed |
| US-4218456-A | 1-(4-Fluorophenyl)-4-(1,2,3,6-tetrahydro-4-phenoxy-1-pyridinyl)-butanones | WARNER-LAMBERT COMPANY (US) | 1980-08-19 | — | — | US | disclosed |
| US-4134982-A | Antipsychotic 1-[4,4-Bis(4-fluorophenyl) butyl]-4-phenoxy-1,2,3,6-tetrahydropyridines | WARNER-LAMBERT COMPANY (US) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | MAPK14 1840/4885CYP3A4 4880/4885SCN4A 3675/4885 |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | MAPK14 1840/4885CYP3A4 4880/4885SCN4A 3675/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | MAPK14 4643/4885CYP3A4 293/4885SCN4A 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.